MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

FDA recall notice · announced May 18, 2022 · Amgen

Class II FDA/FSIS Class II: use may cause temporary or medically reversible adverse health consequences.

The product

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

Reason for recall

Defective container: loose crimp defect, potential loss of container integrity.

Notes

Distribution: Nationwide in the USA, Egypt and Lithuania.
Lot/code information: Lots: 1142258, 1143196, Exp. 09/24
Quantity: 15,823
Status: Terminated
Products in this recall event:
- MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01 (D-0855-2022)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.